Skip to main content

APLS

Stock
Health Care
Biotechnology

Performance overview

APLS Price
Price Chart

Forward-looking statistics

Beta
1.06
Risk
57.52%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Company info

SectorHealth Care
IndustryBiotechnology
Employees748
Market cap$4.9B

Fundamentals

Enterprise value$2.3B
Revenue$775.8M
Revenue per employee—
Profit margin-28.83%
Debt to equity285.94

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.80
Dividend per share—
Revenue per share$6.23
Avg trading volume (30 day)$40M
Avg trading volume (10 day)$39M
Put-call ratio—

Macro factor sensitivity

Growth-2.7
Credit+5.0
Liquidity+2.6
Inflation-2.5
Commodities-1.6
Interest Rates-2.1

Valuation

Dividend yield0.00%
PEG Ratio-21.74
Price to sales2.96
P/E Ratio-21.74
Enterprise Value to Revenue2.94
Price to book13.97

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli

APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.

Zacks Investment Research (July 2, 2025)
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.'s APLS supplemental New Drug Application (sNDA) for Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

Benzinga (April 1, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free